Source-grounded facts extracted from GoodRx Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GoodRx Holdings, Inc. shareholders approved Advisory (non-binding) vote on the compensation of the named executive officers. at the 2026-06-16 meeting.
“Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 2,363,913,370 23,702,520 2,415,838 39,543,093”
GoodRx Holdings, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-16 meeting.
“Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 2,429,055,999 335,716 183,106 0”
GoodRx Holdings, Inc. shareholders approved Election of three Class III directors at the 2026-06-16 meeting.
“Item 1 — Election of three Class III directors for a term of office expiring on the date of the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified or until their respective earlier death, resignation or removal. Votes FOR Votes WITHHELD Broker Non-Votes Wendy Barnes 2,379,952,868 10,078,860 39,543,093 Ronald E. Bruehlman 2,380,863,641 9,168,087 39,543,093 Gregory Mondre 2,382,474,121 7,557,607 39,543,093”
GoodRx Holdings, Inc. reported first quarter of 2026 results: revenue $194.0 million, net income $1.2 million. Guidance raised.
“the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026 . First Quarter 2026 Highlights • Revenue of $194.0 million • Net income of $1.2 million ; Net income margin of 0.6% • Adjusted Net Income 1 of $23.0 million ; Adjusted Net Income Margin 1 of 11.9% • Adjusted EBITDA 1 of $58.3 million ;”
GoodRx Holdings, Inc. dismissed PricewaterhouseCoopers LLP as its auditor.
“approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm”
GoodRx Holdings, Inc. engaged KPMG LLP as its auditor.
“the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026”
Romin Nabiey changed role as Chief Accounting Officer at GoodRx Holdings, Inc..
“Mr. McGinnis succeeds Romin Nabiey who, as previously disclosed, has been serving as Interim Chief Financial Officer.”
Christopher A. McGinnis was appointed as Chief Financial Officer and Treasurer at GoodRx Holdings, Inc..
“On February 4, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer of the Company, effective as of his commencement of employment, which occurred on February 4, 2025 (the “Effective Date”).”
Simon Patterson resigned as Director at GoodRx Holdings, Inc..
“On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee.”
Scott Wagner was appointed as Co-Chair of the Board at GoodRx Holdings, Inc..
“The Board also appointed Mr. Wagner as the Chair of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.”
Scott Wagner was appointed as Class II Director at GoodRx Holdings, Inc..
“On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.”
Romin Nabiey was appointed as Interim Chief Financial Officer at GoodRx Holdings, Inc..
“On January 10, 2025, the Board of Directors (the “Board”) of the Company appointed Romin Nabiey, the Company’s current Chief Accounting Officer, as Interim Chief Financial Officer of the Company, effective as of the Effective Date.”
Karsten Voermann resigned as Chief Financial Officer at GoodRx Holdings, Inc..
“On January 7, 2025, Karsten Voermann submitted his resignation as Chief Financial Officer of GoodRx Holdings, Inc. (the “Company”), effective January 17, 2025 (the “Effective Date”) for personal reasons.”
Ronald E. Bruehlman was elected as Director at GoodRx Holdings, Inc..
“On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.”
Julie Bradley resigned as Director at GoodRx Holdings, Inc..
“On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).”
Ian T. Clark was elected as Class III Director at GoodRx Holdings, Inc..
“On July 8, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ian T. Clark as a Class III director, effective immediately, to fill the vacancy on the Board created by the resignation of Stephen LeSieur.”
Simon Patterson was elected as Class II Director at GoodRx Holdings, Inc..
“On May 29, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Simon Patterson as a Class II director, effective immediately, to fill the vacancy on the Board created by the resignation of Adam Karol.”
GoodRx Holdings, Inc. reported the three months ended March 31, 2024 results: revenue $197.9 million, net income Net loss of $1.0 million.
“for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue 1 and Adjusted Revenue 1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income 1 of $32.6 million; Adjusted Net Income Margin 1 of 16.5% • Adjusted EBITDA 1 of $62.8 million; Adjusted”
Stephen LeSieur resigned as Director at GoodRx Holdings, Inc..
“Also on March 12, 2024, Stephen LeSieur notified the Company of his decision to resign as a member of the Board, effective as of March 14, 2024, including from his service on the Board’s Compliance Committee.”
Adam Karol resigned as Director at GoodRx Holdings, Inc..
“On March 12, 2024, Adam Karol notified the Company of his decision to resign as a member of the Board, effective as of March 22, 2024, including from his service on the Board’s Compliance Committee and Nominating and Corporate Governance Committee.”
GoodRx Holdings, Inc. reported financial results for the three months and year ended December 31, 2023.
“On February 29, 2024, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three months and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report.”
GoodRx Holdings, Inc. entered into Fifth Amendment to First Lien Credit Agreement with Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto (effective 2024-02-20).
“On February 20, 2024, GoodRx, Inc. (“GoodRx”), an indirect wholly-owned subsidiary of GoodRx Holdings, Inc. (the “Company”), entered into the Fifth Amendment to First Lien Credit Agreement (the “Fifth Amendment”), by and among GoodRx, as borrower, GoodRx Intermediate Holdings, LLC and the other guarantors party thereto (collectively, together with GoodRx, the “Loan Parties”), Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto, in order to amend its First Lien Credit Agreement, dated as of October 12, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), to, among other things, extend the maturity date of its $100.0 million revolving credit facility thereunder from October 11, 2024 to July 11, 2025.”
Raj Beri was removed as Chief Operating Officer at GoodRx Holdings, Inc..
“As previously disclosed, on January 16, 2024, the Company determined that the role currently held by Raj Beri, the Company's Chief Operating Officer, would be eliminated and the Company’s Board of Directors removed Mr. Beri as Chief Operating Officer, effective as of February 15, 2024 (the “Separation Date”).”
Raj Beri was removed as Chief Operating Officer at GoodRx Holdings, Inc..
“On January 16, 2024, GoodRx Holdings, Inc. (the “Company”) determined that the role currently held by Raj Beri, the Company's Chief Operating Officer (principal operating officer), will be eliminated and the Company’s Board of Directors removed Mr. Beri as Chief Operating Officer, effective as of February 15, 2024 (the “Effective Date”).”
GoodRx Holdings, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).
“GoodRx Holdings, Inc. (the “Company”) issued a press release announcing the Company’s preliminary estimates of certain financial results for the three months and year ended December 31, 2023.”
Kelly J. Kennedy was elected as Director at GoodRx Holdings, Inc..
“On December 21, 2023, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, elected Kelly J. Kennedy as a Class I director, effective immediately, to fill an existing vacancy on the Board.”
GoodRx Holdings, Inc. reported financial results for three and nine months ended September 30, 2023.
“On November 9, 2023, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three and nine months ended September 30, 2023.”
GoodRx Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $189.7 million, net income $58.8 million.
“Total revenue of $189.7 million, exceeding previously announced guidance • Net income of $58.8 million”
Babak Azad departed as Chief Marketing Officer at GoodRx Holdings, Inc..
“As previously disclosed, on June 27, 2023, GoodRx Holdings, Inc. (the “ Company ”) determined that Babak Azad would no longer serve as Chief Marketing Officer and SVP, Marketing & Communications of the Company, effective July 7, 2023 (the “ Separation Date ”).”
Andrew Slutsky changed role as Chief Marketing Officer at GoodRx Holdings, Inc..
“Andrew Slutsky, currently Senior Vice President of Strategic Marketing Innovation of the Company, will assume an updated Chief Marketing Officer role”
Babak Azad departed as Chief Marketing Officer at GoodRx Holdings, Inc..
“determined that Babak Azad will no longer serve as Chief Marketing Officer, effective July 7, 2023”
GoodRx Holdings, Inc. shareholders approved Advisory (non-binding) approval of the compensation of named executive officers at the 2023-06-14 meeting.
“Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 3,171,107,802 5,186,922 215,580 23,965,043”
GoodRx Holdings, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-14 meeting.
“Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 3,200,128,370 216,960 130,017 0”
GoodRx Holdings, Inc. shareholders approved Election of four Class III directors for a term expiring 2026 at the 2023-06-14 meeting.
“Votes FOR Votes WITHHELD Broker Non-Votes Julie Bradley 3,173,879,841 2,630,463 23,965,043 Dipanjan Deb 3,165,499,138 11,011,166 23,965,043 Stephen LeSieur 3,165,503,620 11,006,684 23,965,043 Gregory Mondre 3,165,056,818 11,453,486 23,965,043”
Jacqueline Kosecoff resigned as member of the Board at GoodRx Holdings, Inc..
“On June 5, 2023, Jacqueline Kosecoff notified the Company of her intent to resign as a member of the Board, effective June 30, 2023”
GoodRx Holdings, Inc. reported the three months ended March 31, 2023 results: revenue $184.0 million, net income $3.3 million.
“or the “Company”) , a leading digital healthcare platform, has released its financial results for the first quarter 2023. First Quarter 2023 Highlights • Total revenue of $184.0 million, exceeding previously announced guidance • Net loss of $3.3 million 1 ; Net loss margin of 1.8% • Adjusted Net Income 2 of $29.5 million; Adjusted Net Income Margin 2 of 16.0% •”
GoodRx Holdings, Inc. reported financial results for the first quarter ended March 31, 2023.
“On April 25, 2023, GoodRx Holdings, Inc. (the “Company”) issued a press release in connection with the executive leadership transition described in Item 5.02 of this Current Report on Form 8-K which addresses the Company’s financial performance for the first quarter ended March 31, 2023.”
Douglas Hirsch changed role as Chief Mission Officer at GoodRx Holdings, Inc..
“Messrs. Bezdek and Hirsch will each remain executive officers of the Company, serving as Chairman and Chief Mission Officer, respectively”
Trevor Bezdek changed role as Chairman at GoodRx Holdings, Inc..
“Messrs. Bezdek and Hirsch will each remain executive officers of the Company, serving as Chairman and Chief Mission Officer, respectively”
Scott Wagner was appointed as Interim Chief Executive Officer at GoodRx Holdings, Inc..
“the Company’s Board of Directors (the “Board”) appointed Scott Wagner as Interim Chief Executive Officer of the Company (principal executive officer), effective April 25, 2023.”
GoodRx Holdings, Inc. reported Full Year 2022 results: revenue $766.6 million, net income $32.8 1 million.
“Full Year 2022 Highlights • Total revenue of $766.6 million • Net loss of $32.8 1 million; Net loss margin of 4.3%”
GoodRx Holdings, Inc. reported Fourth Quarter 2022 results: revenue $184.1 million, net income $2.0 1 million.
“Fourth Quarter 2022 Highlights • Total revenue of $184.1 million, exceeding previously announced guidance • Net loss of $2.0 1 million; Net loss margin of 1.1%”
GoodRx Holdings, Inc. reported the three and nine months ended September 30, 2022 results: revenue $187.3 million, net income $41.7 million.
“(Nasdaq: GDRX), a leading consumer-focused digital platform, has released its financial results for the third quarter of 2022. Third Quarter 2022 Highlights • Total revenue of $187.3 million, exceeding previously announced guidance • Net loss of $41.7 1 million; Net loss margin of 22.3% • Adjusted Net Income 2 of $29.9 million; Adjusted Net Income Margin 2 of 16.0% •”
Raj Beri was appointed as Chief Operating Officer at GoodRx Holdings, Inc..
“the Company also announced the appointment of Raj Beri as Chief Operating Officer, effective May 23, 2022.”
Andrew Slutsky changed role as Senior Vice President, Strategy and Marketing Innovation at GoodRx Holdings, Inc..
“determined that Andrew Slutsky, President, Consumer, and a named executive officer of the Company, would transition to a new role as Senior Vice President, Strategy and Marketing Innovation with the Company in a non-executive officer capacity, which will be effective as of May 9, 2022.”
Karsten Voermann changed role as Chief Financial Officer at GoodRx Holdings, Inc..
“Mr. Nabiey succeeds Karsten Voermann, the Company’s Chief Financial Officer, in such role.”
Romin Nabiey was appointed as Chief Accounting Officer at GoodRx Holdings, Inc..
“On April 20, 2022, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Romin Nabiey, Senior Vice President, Corporate Controller of the Company as the Company’s Chief Accounting Officer and designated Mr. Nabiey as the principal accounting officer of the Company, in each case effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.